Amicus Therapeutics — Technical Presentation (August 2019)
16 slides from Amicus Therapeutics's technical presentation, Aug 1, 2019
Slide 1: Positive Interim Clinical Data from Ongoing Phase 1/2 Study in CLN6 Batten Disease
Positive Interim Clinical Data from Ongoing Phase 1/2 Study in CLN6 Batten Disease August 1, 2019
Slide 2: Forward-Looking Statements
Preliminary Data From Phase 1/2 Study in CLN6 Batten Disease 2 Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of our product candidates, the
Slide 3: Key Takeaways for AAV-CLN6 Gene Therapy
Preliminary Data From Phase 1/2 Study in CLN6 Batten Disease 3 5 Key Takeaways for AAV-CLN6 Gene Therapy Interim Safety and Efficacy Data Demonstrate the Potential for AAV-CLN6 Gene Therapy to Stabilize Progression of a Devastating Disease • Meaningful impact on motor and language function in childr
Slide 4: CLN6 Batten Disease Overview
Preliminary Data From Phase 1/2 Study in CLN6 Batten Disease 4 CLN6 Batten Disease Overview CLN6 Batten Disease is a Fatal Neurologic Disease that Rapidly Robs Children of Their Ability to Walk, Speak, Think, See, and Often Ends in Death During Childhood • Mutation in CLN6 gene leads to lysosomal dy
Slide 5: Hamburg Motor & Language Scale
Preliminary Data From Phase 1/2 Study in CLN6 Batten Disease 5 Hamburg Motor & Language Scale Following Symptom Onset, Natural History Indicates Rapid Degradation of Motor and Language Ability, on the Hamburg Scale, with Each Point Decline Representing Significant Impairment Hamburg Motor & Language
Slide 6: Clinical Study Design
Preliminary Data From Phase 1/2 Study in CLN6 Batten Disease 6 Clinical Study Design Safety and Efficacy of a Single Administration of Intrathecally Delivered AAV-CLN6 Gene Therapy Evaluated for a Number of Key Parameters Including Hamburg Motor + Language Score Intrathecal Administration (dose: 1.5
Slide 7: Baseline Characteristics (n=8)
Preliminary Data From Phase 1/2 Study in CLN6 Batten Disease 7 Baseline Characteristics (n=8) Study Represents a Cross Section of CLN6 Batten Disease with Interim Efficacy Results Now Available for 8 Patients Who Have up to 2 Years of Follow up After Treatment Hamburg Time Between Motor + Age at Enr
Slide 8: Clinical Safety Summary (Interim Data) (n=12)
Preliminary Data From Phase 1/2 Study in CLN6 Batten Disease 8 Clinical Safety Summary (Interim Data) (n=12) Data from an Ongoing 24 Month Single-arm Phase 1/2 Study Indicate Single Intrathecal AAV-CLN6 Administration is Generally Well Tolerated • 12 patients with duration since gene transfer of 6 t
Slide 9: Time to Unreversed 2-Point Decline in Hamburg Motor and Language
Preliminary Data From Phase 1/2 Study in CLN6 Batten Disease 9 Time to Unreversed 2-Point Decline in Hamburg Motor and Language (Comparison to Interim Natural History Data - Unmatched) Time to 2-Point Decline Analysis Suggests Clear Effect of Treatment and Separation of Treated Patients Compared to
Slide 10: Clinical Efficacy: Hamburg M+L Score (n=8)
Preliminary Data From Phase 1/2 Study in CLN6 Batten Disease 10 Clinical Efficacy: Hamburg M+L Score (n=8) Efficacy Data Show a Positive Impact on Motor and Language Function 7 of 8 Patients Maintained Hamburg Score or had an Initial Change (+1 to -1 Points) Followed by Stabilization Patient 7 Treat
Slide 11: CLN6 Clinical Efficacy Data: Sibling Comparisons (Natural History)
Preliminary Data From Phase 1/2 Study in CLN6 Batten Disease 11 CLN6 Clinical Efficacy Data: Sibling Comparisons (Natural History) Treated Patients Demonstrated Stabilization Relative to Untreated Siblings in the Natural History Data Set Who Experienced Substantial Declines in Motor and Language Abi
Slide 12: CLN6 Clinical Efficacy Data: Sibling Comparisons (In-Study)
Preliminary Data From Phase 1/2 Study in CLN6 Batten Disease 12 CLN6 Clinical Efficacy Data: Sibling Comparisons (In-Study) For In-study Pairs, Younger Siblings Demonstrated Increase or No Change in Score Compared to Older Siblings Who had an Initial Change Followed by Stabilization Treated In-Study
Slide 13: CLN6: Clinical Data Summary
Preliminary Data From Phase 1/2 Study in CLN6 Batten Disease 13 CLN6: Clinical Data Summary Interim Safety and Efficacy Data Suggest that AAV-CLN6 Gene Therapy has the Potential to Stabilize Progression of a Devastating Disease that Destroys Brain Function and Kills Children • 12 patients received A
Slide 14: Broad Platform Potential
Preliminary Data From Phase 1/2 Study in CLN6 Batten Disease 14 Broad Platform Potential These Results Also Highlight the Translatability of Results from Mice to NHPs to Humans and Validate the Broad Potential of the Amicus Intrathecal AAV Platform Including CLN3 which is Now in the Clinic Preventio
Slide 15: Phase 1/2 Data Summary and Next Steps
Preliminary Data From Phase 1/2 Study in CLN6 Batten Disease 15 Phase 1/2 Data Summary With these Initial Data we Look Forward to Advancing our Development, Manufacturing and Regulatory Strategy for our Batten Disease Programs • Presentation of additional data in the eight initial patients at the Am
Slide 16: Thank You
Thank You
Amicus Therapeutics — Technical Presentation (August 2019) on 6ix